Rapt Therapeutics (NASDAQ:RAPT - Free Report) - Investment analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for shares of Rapt Therapeutics in a note issued to investors on Tuesday, July 22nd. Lifesci Capital analyst S. Slutsky expects that the company will earn ($0.67) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating and a $31.00 target price on the stock. The consensus estimate for Rapt Therapeutics' current full-year earnings is ($2.14) per share. Lifesci Capital also issued estimates for Rapt Therapeutics' Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.59) EPS.
Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($2.48) by $1.84.
A number of other research firms have also issued reports on RAPT. UBS Group lowered their target price on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. HC Wainwright raised their target price on Rapt Therapeutics to $27.00 and gave the company a "buy" rating in a report on Thursday, July 10th. Finally, Wall Street Zen raised Rapt Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Rapt Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $21.67.
Read Our Latest Report on Rapt Therapeutics
Rapt Therapeutics Trading Down 1.2%
RAPT traded down $0.16 during midday trading on Friday, reaching $13.15. The company's stock had a trading volume of 19,492 shares, compared to its average volume of 112,757. The stock has a market cap of $217.53 million, a P/E ratio of -0.69 and a beta of -0.09. The company has a fifty day simple moving average of $8.88 and a 200 day simple moving average of $8.70. Rapt Therapeutics has a twelve month low of $5.67 and a twelve month high of $27.84.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in RAPT. Simplicity Wealth LLC bought a new position in Rapt Therapeutics during the first quarter worth about $25,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Rapt Therapeutics during the 4th quarter worth approximately $63,000. Sei Investments Co. bought a new position in shares of Rapt Therapeutics during the 4th quarter worth approximately $64,000. Invesco Ltd. lifted its position in shares of Rapt Therapeutics by 411.7% during the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company's stock worth $72,000 after buying an additional 47,391 shares during the period. Finally, Shay Capital LLC bought a new position in shares of Rapt Therapeutics during the 4th quarter worth approximately $81,000. Institutional investors and hedge funds own 99.09% of the company's stock.
Rapt Therapeutics Company Profile
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Featured Stories
Before you consider Rapt Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.
While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access